Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Accumulated Expenses data on file, last reported at $35.1 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $35.1 million, up 574.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.1 million (up 574.77% YoY), and the FY2025 annual result was $18.3 million, up 30.53% from the prior year.
• Accumulated Expenses rose to $35.1 million in Q1 2026 per KYMR's latest filing, from $18.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $35.1 million in Q1 2026 and troughed at $3.6 million in Q1 2023.
• A 5-year average of $16.1 million and a median of $14.0 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses jumped 1538.56% in 2022, then tumbled 82.71% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $8.1 million in 2022, then surged by 315.56% to $33.9 million in 2023, then tumbled by 58.58% to $14.0 million in 2024, then surged by 30.53% to $18.3 million in 2025, then surged by 91.66% to $35.1 million in 2026.
• Business Quant data shows KYMR's Accumulated Expenses at $35.1 million in Q1 2026, $18.3 million in Q4 2025, and $28.6 million in Q3 2025.